Aetna modified CPB 0851 covering palifermin (Kepivance) reimbursement, effective January 5, 2026. Here's what billing teams need to know before submitting claims under J2425.
Aetna, a CVS Health company, updated its palifermin coverage policy under CPB 0851 Aetna system to narrow the covered indication to a specific patient population: members with hematologic malignancies undergoing autologous hematopoietic cell transplantation. The key HCPCS code for palifermin billing is J2425 (injection, palifermin, 50 micrograms). Transplant procedure codes 38240, 38241, and 38242 also appear in this policy. If your oncology or transplant billing team submits J2425 claims for Aetna members, this update sets the exact criteria you must meet to avoid claim denial.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Palifermin (Kepivance) — CPB 0851 |
| Policy Code | CPB 0851 |
| Change Type | Modified |
| Effective Date | January 5, 2026 |
| Impact Level | Medium |
| Specialties Affected | Hematology/Oncology, Bone Marrow Transplant, Radiation Oncology |
| Key Action | Confirm hematologic malignancy diagnosis and WHO grade 3–4 mucositis risk before submitting J2425 claims |
Aetna Palifermin Coverage Criteria and Medical Necessity Requirements 2026
CPB 0851 is Aetna's coverage policy governing palifermin (Kepivance), a keratinocyte growth factor used to prevent and treat severe oral mucositis. The updated policy draws a clear line around who qualifies.
Aetna considers palifermin medically necessary for one indication only: prevention and treatment of severe oral mucositis in members with hematologic malignancies. Those members must also be receiving myelotoxic therapy and require autologous hematopoietic cell transplantation. And the preparative regimen must be one predicted to cause WHO grade 3 or 4 oral mucositis in the majority of patients.
That last criterion matters a lot. WHO grade 3 is severe mucositis — painful ulcerations requiring liquid diet only. WHO grade 4 means the patient cannot eat or drink. Aetna is not covering palifermin for mild or moderate mucositis risk. The clinical bar is high, and your documentation needs to reflect it.
For continuation of therapy, Aetna applies the medical necessity standard as well. The member must have an approved indication and must show documented benefit from therapy. "Benefit" isn't defined further in the policy, so you'll want your clinical team to document measurable improvement — reduced mucositis severity, maintained oral intake, or similar markers.
Prior authorization requirements for J2425 under Aetna plans vary by plan type, but given the specificity of these criteria, you should assume prior auth is required and build that into your workflow before the drug is administered. Retroactive authorization requests on specialty drugs like palifermin rarely go smoothly.
Reimbursement for J2425 depends entirely on meeting these criteria at the time of claim review. If your documentation doesn't clearly establish the hematologic malignancy, the autologous transplant context, and the myeloablative regimen's expected mucositis grade, Aetna will deny the claim.
Aetna Palifermin Exclusions and Non-Covered Indications
The policy is direct here: all other indications for palifermin are considered experimental, investigational, or unproven by Aetna.
That's a broad exclusion. It rules out palifermin for solid tumor malignancies, allogeneic transplant settings (note that 38240 appears in the policy as a related code but is not covered under this CPB), radiation-induced mucositis outside the defined HCT context, Sjogren's syndrome, graft-versus-host disease, and any other off-label uses.
The real issue here is that palifermin has been studied in several other mucositis contexts — including head and neck cancer patients receiving chemoradiation — and some oncologists use it off-label. Aetna is not covering those uses. If your facility administers palifermin in those settings and bills J2425 to Aetna, expect denial. Make sure your oncology team knows this before the drug is ordered for non-HCT patients.
ICD-10 code D89.810 (acute graft-versus-host disease) appears in the policy's related code set, but that's in the broader context of the transplant setting — it's not a standalone covered indication for palifermin. Don't use GvHD alone as the justification for J2425.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Severe oral mucositis prevention/treatment in hematologic malignancy patients receiving myelotoxic therapy + autologous HCT, with WHO grade 3–4 mucositis risk | Covered | J2425, 38241, C81.00–C88.91, K12.31 | Must document hematologic malignancy, autologous HCT context, and grade 3–4 mucositis risk from preparative regimen |
| Continuation of palifermin therapy (covered indication, documented benefit) | Covered | J2425 | Must document clinical benefit from prior therapy |
| All other indications (solid tumors, allogeneic transplant, radiation mucositis outside HCT, GvHD, off-label uses) | Not Covered — Experimental/Investigational | J2425 (denied) | Aetna explicitly excludes all other uses |
Aetna Palifermin Billing Guidelines and Action Items 2026
The policy took effect January 5, 2026. If your team hasn't reviewed active J2425 claims and workflows against these criteria, do it now.
| # | Action Item |
|---|---|
| 1 | Audit your J2425 charge capture against the new criteria. Every J2425 claim to Aetna needs three things in the record: a hematologic malignancy diagnosis (C81.00–C88.91), documentation of autologous HCT (CPT 38241), and a clear statement that the preparative regimen carries WHO grade 3–4 mucositis risk for most patients. If any of those elements are missing, the claim will fail medical necessity review. |
| 2 | Check your ICD-10 coding on J2425 claims. Use K12.31 (oral mucositis, ulcerative, due to antineoplastic therapy) as your primary diagnosis code when billing for palifermin. Pair it with the appropriate hematologic malignancy code from C81.00–C88.91. Don't use K11.9 (salivary gland disease) or R68.2 (dry mouth) as primary codes for palifermin claims — those codes belong in radiation follow-up contexts, not acute mucositis prevention in HCT. |
| 3 | Separate allogeneic transplant cases from the covered population. CPT 38240 (allogeneic transplantation) and 38242 (HPC boost) appear in the policy's related code list, but palifermin is only covered in the autologous context (38241). If your team bills palifermin for allogeneic transplant patients under Aetna, flag those cases before they go out the door. That's a clear exclusion. |
| 4 | Build prior authorization into your J2425 workflow before drug administration. Palifermin is expensive. Aetna's specific criteria make retroactive authorization unlikely to succeed. Your pharmacy or specialty drug team should initiate prior auth with clinical documentation before the drug is ordered. Include the WHO grade prediction from the treating physician in the auth request — that's the detail most teams forget. |
| 5 | Document continuation of therapy explicitly. For ongoing J2425 claims, your records need to show that the member had a covered initial indication and that they experienced measurable benefit. "Patient continues treatment" is not enough. Note reduced mucositis severity, improved oral intake, or decreased pain scores. Give the reviewer something concrete to approve. |
| 6 | Talk to your compliance officer if your facility uses palifermin off-label. If you bill J2425 for head and neck cancer patients, solid tumor patients, or allogeneic transplant patients under Aetna plans, this policy change increases your denial and audit exposure significantly. Map out your current J2425 utilization and flag any cases outside the covered criteria before submitting. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Palifermin (Kepivance) Under CPB 0851
Covered HCPCS Code (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J2425 | HCPCS | Injection, palifermin, 50 micrograms |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| C81.00–C88.91 | Malignant neoplasm of lymphatic and hematopoietic tissue (hematologic malignancies — required for coverage) |
| D89.810 | Acute graft-versus-host disease |
| K11.9 | Disease of salivary gland, unspecified (following radiotherapy) |
| K12.31 | Oral mucositis (ulcerative) due to antineoplastic therapy |
| R68.2 | Dry mouth, unspecified (following radiotherapy) |
| T66.xxxA–T66.xxxS | Radiation sickness, unspecified (following radiotherapy) |
Get the Full Picture for CPT 38241
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.